期刊
TRENDS IN MOLECULAR MEDICINE
卷 18, 期 11, 页码 634-643出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.molmed.2012.09.001
关键词
Huntington disease; spinal muscular atrophy; amyotrophic lateral sclerosis; Alzheimer disease; gene silencing; splice modification; gene therapy
资金
- Canadian Institutes of Health Research (CIHR) [MOP-84438]
- Huntington Society of Canada (HSC)
- Michael Smith Foundation for Health Research (MSFHR)
- ISIS Pharmaceuticals
The rising median age of our population and the age-dependent risk of neurodegeneration translate to exponentially increasing numbers of afflicted individuals in the coming years. Although symptomatic treatments are available for some neurodegenerative diseases, most are only moderately efficacious and are often associated with significant side effects. The development of small molecule, disease-modifying drugs has been hindered by complex pathogenesis and a failure to clearly define the rate-limiting steps in disease progression. An alternative approach is to directly target the mutant gene product or a defined causative protein. Antisense oligonucleotides (ASOs) - with their diverse functionality, high target specificity, and relative ease of central nervous system (CNS) delivery - are uniquely positioned as potential therapies for neurological diseases. Here we review the development of ASOs for the treatment of inherited neurodegenerative diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据